Raymond James reiterates strong buy on Palvella Therapeutics (PVLA)

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $226.00 price target on Palvella Therapeutics (NASDAQ: PVLA).

The reiteration follows Palvella's presentation of two posters at the 2026 Pediatric Dermatology Research Alliance Annual Conference, held October 15-17, 2026. The posters featured pediatric subgroup analyses from the Phase 3 SELVA and Phase 2 TOIVA clinical studies.

The SELVA analysis examined patients aged 6-11 and 12-17, reporting reductions in lesion height, leaking/bleeding, and vesicle appearance following 168 days of treatment with QTORIN rapamycin. The TOIVA pediatric analysis reported improvements in lesion severity and bleeding through Week 24, along with high treatment satisfaction.

Deschner noted that "response to treatment at least trends toward being more favorable in the younger age groups," adding that the data are "very supportive of a broad potential label for QTORIN rapamycin in both the MLM and CVM indications."

Shares of Palvella Therapeutics most recently closed at $127.34.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
• Caldwell sells IQTalent subsidiary to WinMil for C$4.7M